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Assessment of endothelial function 
in relation to the presence of type 2 
diabetes mellitus in patients with prior 
myocardial infarction: a pilot study using 
peripheral arterial tonometry
ABSTRACT
Background. Endothelial dysfunction represents an early stage of atherosclerosis, while hyperglycaemia 
remains an important cause of endothelial dysfunction. The aim of this study was to assess endothelial 
function in patients with prior ST-segment elevation myocardial infarction (STEMI) in relation to the presence 
of type 2 diabetes mellitus (DM).
Materials and methods: Eighty three adults treated with primary percutaneous intervention for STEMI 
within the previous 12–18 months were enrolled in a case-control study. The control group consisted of 
21 healthy volunteers. Endothelial function was assessed with peripheral arterial tonometry (PAT). The value 
of reactive hyperemia index (RHI) and the presence of endothelial dysfunction (defined as RHI ≤ 2.0) were 
respectively the primary and secondary study endpoints.
Results. RHI was significantly lower in post-STEMI subjects with concomitant type 2 DM (n = 21) than in healthy 
volunteers [1.70 (1.44–1.96) vs 2.15 (1.82–2.50); p = 0.006]. On the other hand, there were no significant 
differences in RHI between post-STEMI patients with and without type 2 DM [n = 62; RHI: 1.87 (1.59–2.39)], 
nor between the latter group and the control group. In terms of the secondary study endpoint, we observed 
a decreasing prevalence of endothelial dysfunction across the compared groups [76.2% vs 54.8% vs 38.1% 
for post-STEMI diabetics, post-STEMI non-diabetics and controls, respectively; p for trend = 0.013].
Conclusions. Our study indicates that endothelial function assessed with PAT is significantly worse in 
post-STEMI subjects with concomitant type 2 DM compared to healthy controls, but it does not seem 
to be substantially different in diabetic vs. non-diabetic STEMI survivors. The clinical significance of our 
findings warrants further investigation in adequately powered, prospective studies.
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Introduction
The endothelium produces substances that exert 
autocrine and paracrine effects and play a key role in 
maintaining vascular homeostasis [1–3]. Endothelial 
dysfunction is characterized by reduced bioavailability 
of vasodilatory mediators, particularly nitric oxide, and 
increased production of vasoconstrictive mediators, 
including endothelin 1. Numerous proinflammatory, 
proliferative and prothrombotic mechanisms are 
activated in dysfunctional endothelium in addition to 
the impairment of endothelium–dependent vasodila-
tation. Activated endothelium subsequently initiates 
adverse mechanisms underlying the development 
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and destabilization of atherosclerotic plaque [4, 5]. 
Endothelial dysfunction represents an early stage 
of atherosclerosis development – the main cause of 
coronary artery disease [5, 6], which in turn is the 
leading cause of morbidity and mortality in industri-
alized countries [7, 8]. 
Classic risk factors of coronary artery disease 
possess a limited value in predicting adverse clinical 
outcomes in patients after an acute coronary syndrome 
[9, 10]. It is estimated that in this population classic risk 
factors explain less than 50% of the risk of recurrent car-
diovascular events [9, 10]. The consequence of these 
findings is that a great interest is taken in methods that 
could significantly improve the risk stratification in this 
group of patients. Great expectations in this regard lie 
in the assessment of endothelial function. To date, it 
has been clearly demonstrated that the presence of 
dysfunctional endothelium in coronary and peripheral 
arteries is an independent risk factor of future cardio-
vascular events [6, 8, 11–15].
Diabetes mellitus constitutes one of the main risk 
factors for coronary artery disease. It is estimated that 
it occurs in 6.4% of adults and in 20–25% of patients 
with a recent acute coronary syndrome [16]. The risk of 
death from cardiovascular causes is similar for patients 
with diabetes without prior myocardial infarction as it 
is for those with a history of myocardial infarction but 
without concomitant diabetes [17]. Mortality among 
patients with myocardial infarction and diabetes remains 
significantly higher compared to non-diabetics [18]. 
The aim of this study was to assess endothelial 
function using peripheral arterial tonometry (PAT) in 
patients with prior ST-segment elevation myocardial 
infarction (STEMI) in relation to the presence of type 2 
diabetes mellitus.
Materials and methods 
Study design and population characteristics
Eighty-three patients hospitalized between No-
vember 2005 and December 2008 for a first episode of 
STEMI and treated with primary percutaneous coronary 
intervention were enrolled in a case-control study. The 
cases were consecutive patients from a prospective, 
cohort study assessing glucose metabolism disorders 
and post-STEMI left ventricular systolic dysfunction. 
STEMI was diagnosed in accordance with international 
recommendations [19, 20]. The STEMI survivors were 
divided into two groups according to concomitant 
disturbances of glucose metabolism. The first group 
comprised patients with type 2 diabetes mellitus and 
the second group comprised non-diabetic individu-
als. Diabetes mellitus was defined as: fasting plasma 
glucose concentration ≥ 126 mg/dL (7.0 mmol/L) in at 
least two measurements, or plasma glucose concentra-
tion ≥ 200 mg/dL (11.1 mmol/L) at 120 minutes of oral 
glucose tolerance test (OGTT). OGTT was performed 
before hospital discharge (STEMI hospitalization) and 
three months after. Patients without diagnosed diabetes 
mellitus had another OGTT performed on the day of 
endothelial function assessment (12–18 months after 
STEMI). Glucose, lipid profile and HbA1c assays were 
performed using standard methods on the Architect 
ci8200 analyzer (Abbott Laboratories, Wiesbaden, 
Germany). We also recruited 21 healthy volunteers as 
a control group.
The value of reactive hyperemia index (RHI) was the 
primary study endpoint, while the presence of endothe-
lial dysfunction (defined as RHI ≤ 2.0) constituted the 
secondary study endpoint.
The study protocol was approved by The Ethical 
Committee of Nicolaus Copernicus University (KB 
74/2009). 
Assessment of endothelial function
Endothelial function was assessed using PAT (the 
EndoPAT 2000 device, Itamar-Medical, Caesarea, 
Israel), which is a non-invasive, user-friendly and 
well-validated in terms of clinical outcomes prediction, 
diagnostic tool [2, 4, 8, 21–23]. The device provides 
reliable and reproducible results. The principle of PAT 
has been described in detail previously [2]. Briefly, 
the EndoPAT 2000 device utilizes the applanation 
tonometry method. A blood pressure cuff is placed on 
one arm, while the other arm acts as the control arm. 
Dedicated PAT probes are placed on one finger of each 
hand to assess digital volume changes accompany-
ing pulse waves [6]. After a ten minute equilibration 
period, the cuff is inflated to 60 mm Hg above systolic 
pressure for five minutes with subsequent deflation 
of the cuff resulting in reactive hyperemia (RH) [21]. 
Computerized automatic analysis provides RH-PAT 
indices as a measure of reactive hyperemia. The 
parameter used to evaluate endothelial function is 
the reactive hyperemia index (RHI). According to the 
device’s manufacturer, normal RHI values are those 
exceeding 2.0, while in terms of values lower or equal 
to 2.0, endothelial dysfunction is diagnosed [24]. The 
EndoPAT 2000 device is approved for use in the Eu-
ropean Union (CE certificate) and in the United States 
of America (by the FDA).
All study participants fasted for 12 hours be-
fore assessments, which were carried out at 
09:00 a.m. ± 1 hour, in temperatures of 22°C ± 1°C. 
In addition, smokers were asked to abstain from 
cigarettes for at least 12 hours before endothelial 
function assessment.
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Statistical analysis 
According to the Shapiro-Wilk test, the investigated 
continuous variables were non-normally distributed. 
Therefore, the results were reported as medians and 
interquartile ranges and non-parametric tests were ap-
plied in the statistical analysis. For comparisons among 
three groups, the Kruskal-Wallis (for assessment of 
heterogeneity), with the application of an appropriate 
post hoc test, and the Jonckheere-Terpstra (for evalu-
ation of a trend) tests were used. Categorical variables 
were expressed as a number of patients presenting 
the given feature and a percentage of those patients in 
the analyzed group. Comparisons of categorical vari-
ables were performed using the c2 test with the Yates’ 
correction if required. The presence or absence of 
trends among categorical variables was assessed with 
the Cochran-Armitage test. ROC (Receiver Operating 
Characteristic) curve analysis was used to determine 
the diagnostic value of RHI to identify patients after myo-
cardial infarction with concomitant diabetes. Differences 
were considered significant at p<0.05. The statistical 
analysis was carried out using the Statistica 10.0 pack-
age (StatSoft, Tulsa, OK, USA), SPSS Statistics version 
19.0 (SPSS Inc., Chicago, IL, USA) and MedCalc version 
12.1 (MedCalc Software, Mariakerke, Belgium).
Results
Patients
Of the 83 post-STEMI patients constituting our study 
group, 21 had type 2 diabetes mellitus, whereas the 
remaining 62 were free from this metabolic disorder. 
The clinical characteristics of the study participants 
are presented in Table 1. Post-STEMI patients with 
concomitant diabetes mellitus compared with non-di-
abetic post-STEMI patients and the control groups had 
a significantly higher body mass index and glycated he-
moglobin concentration measured on the day of endo-
thelium function assessment. Additionally, post-STEMI 
diabetic patients presented with substantially higher 
systolic blood pressure on the day of endothelium 
function assessment as compared with other groups.
Endothelial function
As shown in Figure 1, we demonstrated the pres-
ence of significant heterogeneity in RHI values among 
the compared groups. The use of the post hoc test 
revealed a substantially lower RHI value in post-STEMI 
subjects with concomitant type 2 DM than in controls 
[1.70 (1.44–1.96) vs 2.15 (1.82–2.50), p = 0.006]. On 
the other hand, there were no significant differences in 
RHI between post-STEMI patients with and without type 
2 DM [RHI: 1.87 (1.59–2.39)], nor between the latter 
group and the control group. 
In terms of the secondary study endpoint, we 
observed a decreasing prevalence of endothelial dys-
function across the compared groups [16/21 (76.2%) vs 
34/62 (54.8%) vs 8/21 (38.1%) for post-STEMI diabetics, 
post-STEMI non-diabetics and controls, respective-
ly; Fig. 2]. Endothelial dysfunction was significantly 
more frequent among post-STEMI patients with type 2 
diabetes mellitus compared with controls [odds ratio 
(OR) 5.20; 95% confidence interval (CI) 1.37–19.77; 
p = 0.016]. On the other hand, differences in the prev-
alence of endothelial dysfunction between post-STEMI 
patients without diabetes mellitus and controls (OR 
1.97; 95% CI 0.72–5.43; p = 0.188) as well as between 
diabetic and non-diabetic STEMI survivors (OR 2.64; 
95% CI 0.86–8.09; p = 0.09; Fig. 2) did not achieve 
statistical significance. 
Additionally, we performed a ROC curve analysis 
among all study participants (both post-STEMI pa-
tients and healthy volunteers) in order to determine 
the diagnostic value of RHI in identification of diabet-
ic patients (Fig. 3). The area under the ROC curve 
(AUC) achieved an acceptable value of 0.693 (95% CI 
0.595–0.780; p < 0.001). The optimal cut-off value of 
RHI for identification of patients with type 2 diabetes 
mellitus was 2.02. The sensitivity, specificity, positive 
predictive value and negative predictive value for this 
cut-off point were 81.0% (95% CI 58.1–94.4%), 47.0% 
(95% CI 35.9–58.3%), 27.9% (95% CI 17.2–40.8%) and 
90.7% (95% CI 77.8–97.3%), respectively.
Discussion
The present study demonstrates that endothelial 
function, assessed with PAT as a continuous variable 
(RHI) or evaluated in a qualitative way as the presence 
of endothelial dysfunction, is significantly impaired in 
post-STEMI patients with concomitant type 2 diabetes 
mellitus compared with healthy controls. Comparing 
the control group vs. non-diabetic post-STEMI patients 
vs. post-STEMI patients with concomitant type 2 diabe-
tes mellitus, we observed a gradual deterioration of en-
dothelial function, with an increase in total cardiovascu-
lar risk. We also found that RHI possesses a significant 
discriminating value in terms of identification of patients 
with diabetes mellitus, with particularly high sensitivity 
(for RHI values ≤ 2.02) and high negative predictive val-
ue (for RHI values > 2.02), but with low specificity and 
low negative predictive value. Nevertheless, our results 
indicate that endothelial function assessed with PAT 
does not seem to be substantially different in diabetic 
vs non-diabetic STEMI survivors.
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Table 1. Characteristics of the study population 
Variable Post-STEMI 
patients with 
type 2 diabetes 
mellitus  
(n = 21)
Post-STEMI 
patients without 
type 2 diabetes 
mellitus (n = 62)
Control group
(n = 21)
p-value for 
comparison 
between 
post-STEMI 
diabetic 
and non-
diabetic 
patients
p-value  
for compa- 
rison  
among all 
analyzed  
groups
Demographic and clinical characteristics
Male, n (%) 13 (61.9) 46 (74.2) 9 (42.9) ns 0.031
Age (years) 64.0 (60.0–71.0) 59.5 (54.0–67.0) 58.0 (54.0–63.0) ns ns
Body mass index [kg/m2] 29.9 (25.6–33.7) 27.4 (25.2–29.2) 24.2 (22.4–25.6) 0.043 0.006
History of hypertension, n (%) 14 (66.7) 31 (50.0) 0 (0) ns na
Current smokers, n (%) 9 (42.9) 31 (50.0) 1 (4.8) ns 0.001
History of hypercholesterolemia, 
n (%)
6 (28.6) 23 (37.1) 0 (0) ns na
Pharmacotherapy on the day of endothelial function assessment
Aspirin, n (%)
Clopidogrel, n (%)
Beta-blocker, n (%)
ACEI/ARB, n (%)
Statin, n (%)
Ca-blocker, n (%)
Diuretics, n (%)
Insulin, n (%)
Oral antidiabetic agents, n (%)
Metformin, n (%)
21 (100.0)
3 (14.2)
20 (95.2)
21 (100.0)
20 (95.2)
4 (19.1)
9 (42.9)
9 (42.9)
9 (42.9)
6 (28.6)
59 (95.2)
9 (14.5)
61 (98.4)
57 (91.9)
56 (90.3)
6 (9.7)
9 (14.5)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
ns
ns
ns
ns
ns
ns
0.016
< 0.0001
< 0.0001
< 0.0001
na
na
na
na
na
na
na
na
na
na
Blood pressure and laboratory parameters on the day of endothelial function assessment
Systolic blood pressure [mm Hg] 130 (120.0–140.0) 115.0 (100.0–130.0) 120.0 (110.0–125.0) 0.044 0.047
Diastolic blood pressure [mm Hg] 80.0 (70.0–80.0) 70.0 (70.0–80.0) 70.0 (70.0–80.0) ns ns
Total cholesterol [mg/dL] 163.0 (152.0–184.0) 166.0 (145.0–195.0) 227.0 (206.0–250.0) ns < 0.0001
LDL-C [mg/dL] 91.0 (78.0–107.0) 96.0 (78.5–117.0) 152.0 (127.0–164.0) ns < 0.0001
HDL-C [mg/dL] 46.0 (41.0–52.0) 48.0 (40.0–53.0) 53.0 (45.0–63.0) ns ns
Triglycerides [mg/dL] 140.0 (88.0–194.0) 96.0 (76.0–140.0) 117.0 (85.0–159.0) ns  ns
HbA1c (%) 6.5 (6.2–8.0) 5.6 (5.3–5.8) 6.0 (5.8–6.2) < 0.0001 < 0.0001
ACE-I — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; HbA1c — glycated haemoglobin; HDL-C — high density 
lipoprotein cholesterol; LDL-C — low density lipoprotein cholesterol; na — not applicable due to the fact that assumptions of the c2 test are not 
fulfilled; ns — non significant
Chronic hyperglycemia plays a dominant role in the 
deterioration of endothelial function in patients with dia-
betes mellitus. It enhances oxidative stress by generating 
a variety of reactive oxygen species through activation 
of several biochemical pathways including: stimulation 
of the polyol pathway, increased transcription of genes 
for proinflammatory cytokines and plasminogen acti-
vator inhibitor-1 (PAI-1), activation of protein kinase-C, 
increased synthesis of advanced glycation end products 
(AGEs) and autooxidation of glucose with formation of 
ketoimines and AGEs [2, 25, 26]. Additionally, impair-
ment of nitric oxide-dependent vasodilator effect of 
insulin related to insulin resistance [27] and low count of 
dysfunctional endothelial progenitor cells were shown in 
type 2 diabetes mellitus [28]. Furthermore, repeated and 
extensive exposure of endothelial cells to hyperglycemia 
accompanied by other cardiovascular risk factors impairs 
their vascular protective function [28, 29].
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Figure 1. Comparison of reactive hyperemia indices in 
post--STEMI patients with concomitant type 2 diabetes 
mellitus (prior MI, DM present group), non-diabetic post-
STEMI patients (prior MI, DM absent group) and healthy 
volunteers (control group). DM — diabetes mellitus; MI 
— myocardial infarction; STEMI — ST-segment elevation 
myocardial infarction. Statistical significance of p was 
calculated for heterogeneity among the compared 
groups
Figure 2. Presence of endothelial dysfunction in post- 
-STEMI patients with concomitant type 2 diabetes mellitus 
(prior MI, DM present group), non-diabetic post-STEMI 
patients (prior MI, DM absent group) and healthy volunteers 
(control group). DM — diabetes mellitus; MI — myocardial 
infarction; STEMI — ST-segment elevation myocardial 
infarction 
Figure 3. ROC curve assessing the diagnostic value of 
reactive hyperemia index to identify patients with type 
2 diabetes. RHI — reactive hyperemia index
The use of applanation tonometry was prompted 
by the modernity of this automated data analysis, its 
simplicity of use, and operator independence. Impor-
tantly, the location of the plethysmograph probe on 
a finger prevents accumulation of distal venous blood, 
which may cause venous-arterial vasoconstriction. 
It also increases the dynamic range of changes of 
blood volume through arterial wall relief, prevents the 
backflow of venous blood that could adversely affect 
the measurement, as well as reduces artifacts caused 
by limb movements. Furthermore, simultaneous re-
cording of blood flow on the opposite arm eliminates 
the influence of the autonomic nervous system on the 
vessels’ wall tension changes [24]. The result not only 
shows a relationship with the occurrence of coronary 
artery disease risk factors [30], but also has a significant 
prognostic value in predicting cardiovascular events, 
independent of traditional risk scores [31]. Moreover, 
the results of endothelial function measurement using 
applanation tonometry correlate with endothelial dys-
function assessed with invasive [6, 8] and non-invasive 
methods, such as ultrasound assessment of arterial 
dilatation as a consequence of ischemia [8, 32, 33]. 
Contrary to the latter modality being to date the most 
widely used method acknowledged as a gold standard 
of non-invasive techniques of endothelial function as-
sessment, applanation tonometry is standardized and 
has high repeatability of measurements [34, 35]. These 
properties encourage the use of applanation tonometry 
in clinical practice. A significant correlation has been 
demonstrated between the value of RHI and the pres-
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ence of cardiovascular disease risk factors such as: 
male gender, body mass index, total cholesterol/HDL, 
diabetes mellitus, smoking and the treatment of lipid 
disorders [30, 33, 36–39]. 
Ruggiero et al. showed significantly impaired endo-
thelial function, as assessed with applanation tonome-
try, in diabetic patients without coronary artery disease 
compared to healthy subjects [40]. Furthermore, Gar-
giulo et al. evaluated endothelial function using PAT in 
183 consecutive patients undergoing elective coronary 
angiography in relation to the presence of concomitant 
type 2 diabetes mellitus. Subjects with prior myocardial 
infarction were excluded from the study. The authors re-
ported that diabetic patients, regardless of the presence 
of coronary artery disease, demonstrated a significantly 
higher impairment of peripheral vascular function than 
non-diabetic patients without coronary artery disease [41]. 
Importantly, diabetic patients without coronary artery 
disease (n = 58) showed a similar degree of endothelial 
dysfunction compared with patients with established 
coronary artery disease without concomitant glucose 
metabolism disorders (n = 31). Gargiulo et al. have also 
demonstrated significantly worse endothelial function in 
patients with coronary artery disease, but without type 
2 diabetes mellitus, compared with healthy subjects 
(n = 36). In line with our findings, the authors observed 
comparable RHI values in coronary artery disease 
patients with (n = 58) and without concomitant type 
2 diabetes mellitus.
In our study, contrary to expectations, we did not find 
major differences in endothelial function between post-
STEMI patients without diabetes mellitus compared 
with healthy subjects, even though the post-STEMI 
patients were additionally burdened with hypertension 
(50%) and were more likely to be smokers than controls 
(50.0% vs 4.8%). The only risk factor that was more 
pronounced in the control group was worse lipid profile 
values. This lack of differences could be potentially 
explained by the proven, beneficial effects on endothe-
lium of drugs such as angiotensin-converting enzyme 
inhibitors and statins, used in the post-STEMI setting. 
Furthermore, we were analyzing only one index of en-
dothelial function, while other indicators of endothelial 
function can possibly show differences.
Lumsden et al. evaluated endothelial function using 
applanation tonometry in 15 patients with type 2 dia-
betes mellitus suffering from recent acute coronary 
syndrome. They demonstrated that these patients, 
despite remaining on standard clinical care within six 
months after acute coronary syndrome, continued to 
show significantly worse endothelial function compared 
with 16 healthy subjects [42]. Similarly to their results, 
we found that diabetic patients on optimal medical 
treatment continue to show significant impairment of 
endothelial function after at least one year of STEMI.
Despite advances that have taken place in recent 
years regarding the diagnostics and treatment of pa-
tients with acute coronary syndromes and diabetes mel-
litus, the prognosis in this group remains worse than in 
patients without diabetes mellitus. Endothelial dysfunc-
tion, which plays a key role not only in the development 
of atherosclerosis but also in the process of restenosis, 
remains a diagnostic and therapeutic challenge. The 
complex processes underlying endothelial dysfunction 
in diabetic individuals require further exploration, so we 
can effectively fill the gaps in currently used therapies 
and therefore provide the best help to our patients.
Limitations of the study
Due to a limited number of patients with type 2 dia-
betes mellitus, the results need confirmation in a larger 
population. In this pilot study, we examined only endo-
thelial vasodilator function. In the next phase, we plan to 
assess other indicators of endothelial function in similar 
groups of patients. Further studies are needed to evalu-
ate the clinical significance of the observed relations. We 
cannot overlook the fact that in our study all enrolled 
patients after myocardial infarction received drugs with 
proven, beneficial effects on endothelial function.
 Conclusions 
Our study indicates that endothelial function as-
sessed with PAT is significantly worse in post-STEMI 
subjects with concomitant type 2 diabetes mellitus com-
pared with healthy controls. It does not seem however 
to be substantially different in diabetic vs. non-diabetic 
STEMI survivors. The clinical significance of our findings 
warrants further investigation in adequately powered, 
prospective studies.
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